Incyte (NASDAQ:INCY) Issues Earnings Results

Incyte (NASDAQ:INCY) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $3.09 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94, FiscalAI reports. The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.50 billion. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The company’s revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.57 EPS.

Here are the key takeaways from Incyte’s conference call:

• Broad-based commercial growth: Second-quarter net product sales rose 40% year over year, or 17% excluding a $246 million one-time CMS-related benefit. Jakafi, OPZELURA, Niktimvo, MONJUVI, and ZYNYZ all posted higher sales, supporting management’s strategy to diversify beyond Jakafi.
• Guidance was raised: Full-year 2026 total net sales guidance increased to $5.13 billion-$5.26 billion, with OPZELURA guidance raised to $1.05 billion-$1.10 billion and hematology/oncology guidance increased to $860 million-$890 million.
• Jakafi XR launch is progressing: The company is on track for 50%-70% formulary coverage by year-end, while physician adoption is expected to accelerate through 2027. Jakafi XR sales are projected at approximately $40 million-$50 million in 2026.
• Pipeline and regulatory catalysts remain substantial: Incyte expects multiple approvals, launches, and data readouts in the second half of 2026, including OPZELURA in European atopic dermatitis, povorcitinib studies, and oncology updates at ESMO for its G12D, TGF-beta/PD-1, and CDK2 programs.
• One clinical program was discontinued: Incyte halted development of INCA058, its lead JAK2 V617F-targeted asset, citing an insufficiently differentiated efficacy, safety, and pharmacokinetic profile. The company plans to prioritize next-generation JAK2 programs instead.

Incyte Trading Down 3.5%

INCY stock traded down $4.50 during midday trading on Thursday, reaching $122.60. The company’s stock had a trading volume of 897,782 shares, compared to its average volume of 1,785,025. Incyte has a 52 week low of $73.81 and a 52 week high of $132.60. The stock has a market cap of $24.49 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 1.13 and a beta of 0.76. The company has a quick ratio of 3.60, a current ratio of 4.53 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $108.59 and its 200-day simple moving average is $102.00.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q2 results exceeded expectations: Incyte reported $3.09 in adjusted earnings per share versus a $2.15 consensus estimate, while revenue reached $1.67 billion, above the $1.50 billion forecast. Revenue increased 37.7% year over year, supported by stronger Jakafi and Opzelura sales. INCY Q2 Earnings and Revenues Beat
• Positive Sentiment: 2026 outlook was raised sharply: Management now expects total net sales of $5.13 billion to $5.26 billion, up from $4.77 billion to $4.94 billion previously. Opzelura sales guidance increased to $1.05 billion-$1.10 billion, putting the product on track to exceed $1 billion this year. Incyte Raises 2026 Sales Forecast
• Positive Sentiment: CMS settlement strengthened Opzelura economics: The agreement is expected to contribute approximately $300 million-$310 million to 2026 Opzelura sales, including a one-time $246 million non-cash benefit recognized in the second quarter. Investors also received reassurance that growth is broadening beyond Jakafi, with Niktimvo, Monjuvi and Zynyz contributing to the portfolio.
• Positive Sentiment: Analysts lifted targets: HC Wainwright raised its target to $150 and maintained a Buy rating, while BMO increased its target to $130. Analysts cited the earnings beat, higher guidance, commercial momentum and progress across the development pipeline. Analysts Raise Incyte Forecasts
• Neutral Sentiment: Momentum coverage is supportive but not a new fundamental catalyst: Zacks highlighted INCY’s strong growth and momentum style scores, while UBS retained a Hold rating with a $113 target, suggesting some analysts believe much of the improved outlook is already reflected in the stock. UBS Maintains Hold on Incyte
• Negative Sentiment: Pipeline pruning adds a modest risk: Incyte discontinued a Phase 1 JAK inhibitor program to focus resources on next-generation candidates, reducing one development opportunity even as management emphasizes a broader pipeline. Incyte Discontinues Early-Stage JAK Program

Analyst Ratings Changes

Several analysts have recently commented on the stock. UBS Group increased their price target on shares of Incyte from $103.00 to $113.00 and gave the company a “neutral” rating in a research note on Friday, June 26th. BMO Capital Markets boosted their price objective on shares of Incyte from $112.00 to $130.00 and gave the stock a “market perform” rating in a research report on Wednesday. Citigroup reaffirmed a “market perform” rating on shares of Incyte in a report on Wednesday, July 15th. Stifel Nicolaus set a $145.00 target price on Incyte in a research note on Tuesday. Finally, Royal Bank Of Canada boosted their target price on Incyte from $99.00 to $109.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Eight research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to MarketBeat.com, Incyte has a consensus rating of “Hold” and a consensus price target of $117.74.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. MUFG Securities EMEA plc bought a new stake in Incyte in the second quarter valued at about $32,000. CYBER HORNET ETFs LLC bought a new position in Incyte during the second quarter worth about $33,000. Atlas Capital Advisors Inc. bought a new position in Incyte during the fourth quarter worth about $35,000. Geneos Wealth Management Inc. grew its position in shares of Incyte by 350.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 588 shares during the period. Finally, CIBC Private Wealth Group LLC grew its position in shares of Incyte by 153.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 726 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 440 shares during the period. 96.97% of the stock is currently owned by institutional investors.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.